Marker Therapeutics Inc 2026年季度报告

FORM10-Q ☒Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2026☐Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to_____. Commission File Number:001-37939 MARKER THERAPEUTICS,INC. (Name of registrant in its charter) Houston, Texas77021(Address of principal executive offices)(Zip Code) (713) 400-6400(Issuer’s telephone number) Securities registered pursuant to Section12(b)of the Act: Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to besubmittedpursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorterperiod that the registrant was required to submit such files). Yes☒No☐ Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒ The registrant had 16,673,127 shares of common stock outstanding as of August 07, 2026. PART I – FINANCIAL INFORMATION1Item1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets As of June 30, 2026 and December 31, 20251Condensed Consolidated Statements of Operations for the three and six months ended June 30,2026 and 20252Condensed Consolidated Statements of Stockholders’ Equity for the three and six months endedJune 30, 2026 and 20253Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and20254Notes to Condensed Consolidated Financial Statements5Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations.17Item3.Quantitative and Qualitative Disclosures About Market Risk.28Item4.Controls and Procedures.28PART II – OTHER INFORMATION29Item1.Legal Proceedings.29Item1A.Risk Factors.29Item2.Unregistered Sales of Equity Securities and Use of Proceeds.29Item3.Defaults Upon Senior Securities.29Item4.Mine Safety Disclosure.29Item5.Other Information.29Item6.Exhibits.30Signatures31 PART I.FINANCIAL INFORMATION Item 1.Financial Statements MARKER THERAPEUTICS,INC.CONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED) MARKER THERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED) MARKER THERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED) MARKER THERAPEUTICS,INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED) MARKER THERAPEUTICS,INC.NOTESTO CONDENSED CONSOLIDATED FINANCIAL STATEMENTSJune 30, 2026(Unaudited) NOTE1: NATURE OF OPERATIONS Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncologycompany specializing in the development and commercialization of novel T cell-based immunotherapies for thetreatment of hematological malignancies and solid tumor indications. The Company’s Multi-Antigen Recognizing(“MAR”)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells thatrecognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These Tcells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. The Company wasincorporated in Nevada in 1992 and reincorporated in Delaware in October 2018. Currently, the Baylor College of Medicine (“BCM”) supplies the Company with its Multi-Antigen Recognizing(MAR)-T cell products, including MT-601, the Company’s lead MAR-T cell product. On June 16, 2025, the Company entered into a Statement of Work (the “SOW”) with Cellipont Bioservices(“Cellipont”), a leading cell therapy Contract Development and Manufacturing Organization (“CDMO”), for themanufacturing of MT-601. Pursuant to the SOW, Cellipont will provide technology transfer and cGMP manufacturingservices to support the scale-up and production of MT-601 for the Company’s APOLLO study. NOTE2: BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the